Takeda Pharmaceutical Co (MEX:TAK) Interest Expense : MXN-18,319 Mil (TTM As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Takeda Pharmaceutical Co Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Takeda Pharmaceutical Co's interest expense for the three months ended in Sep. 2024 was MXN -9,429 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2024 was MXN-18,319 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Takeda Pharmaceutical Co's Operating Income for the three months ended in Sep. 2024 was MXN 37,691 Mil. Takeda Pharmaceutical Co's Interest Expense for the three months ended in Sep. 2024 was MXN -9,429 Mil. Takeda Pharmaceutical Co's Interest Coverage for the quarter that ended in Sep. 2024 was 4.00. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Takeda Pharmaceutical Co Interest Expense Historical Data

The historical data trend for Takeda Pharmaceutical Co's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takeda Pharmaceutical Co Interest Expense Chart

Takeda Pharmaceutical Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Interest Expense

Get a 7-Day Free Trial

-32,451.70

-24,598.23

-20,558.25

-15,774.13

-13,241.57

Takeda Pharmaceutical Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Interest Expense	Get a 7-Day Free Trial															-6,836.07	-7,847.83	5,885.29	-6,927.31	-9,428.77

Takeda Pharmaceutical Co Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-18,319 Mil.

Takeda Pharmaceutical Co (MEX:TAK) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Takeda Pharmaceutical Co's Interest Expense for the three months ended in Sep. 2024 was MXN-9,429 Mil. Its Operating Income for the three months ended in Sep. 2024 was MXN37,691 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2024 was MXN609,782 Mil.

Takeda Pharmaceutical Co's Interest Coverage for the quarter that ended in Sep. 2024 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Sep. 2024 )	/	Interest Expense (Q: Sep. 2024 )
	=	-1	*	37690.546	/	-9428.766
	=	4.00

The higher the ratio, the stronger the company's financial strength is.

Warning Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Takeda Pharmaceutical Co Ltd interest coverage is 3.36, which is low.

Takeda Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Takeda Pharmaceutical Co Ltd (MEX:TAK) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

TAK:USA TKPHF:USA 4502:Japan 0A87:UK TKDA:Germany TAKP34:Brazil TKD:Austria

Address

1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668

Website

https://www.takeda.com

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.